Nature Communications · 2015 · 497 citations · 52 references
Life SciencesImmunologyOncologyCancer ImmunologyImmunotherapyTumor ImmunologyCancer Cell SignalingCancer ImmunotherapyChemokine SignalingImmune Cell TraffickingImmune Checkpoint RegulationLeukocyte TraffickingCd8 Positive T CellsChemokine BiologyChemokine-mediated TraffickingChemokines In Tumor MicroenvironmentG Protein-coupled Chemokine ReceptorsT Cell Trafficking To TumorsT Cell-based ImmunotherapyT-cell Trafficking
T-cell trafficking at vascular sites has emerged as a key step in antitumour immunity. Chemokines are credited with guiding the multistep recruitment of CD8+ T cells across tumour vessels. However, the multiplicity of chemokines within tumours has obscured the contributions of individual chemokine receptor/chemokine pairs to this process. Moreover, recent studies have challenged whether T cells require chemokine receptor signalling at effector sites. Here we investigate the hierarchy of chemokine receptor requirements during T-cell trafficking to murine and human melanoma. These studies reveal a non-redundant role for Gαi-coupled CXCR3 in stabilizing intravascular adhesion and extravasation of adoptively transferred CD8+ effectors that is indispensable for therapeutic efficacy. In contrast, functional CCR2 and CCR5 on CD8+ effectors fail to support trafficking despite the presence of intratumoral cognate chemokines. Taken together, these studies identify CXCR3-mediated trafficking at the tumour vascular interface as a critical checkpoint to effective T-cell-based cancer immunotherapy. Tumours secrete many lymphocyte-attracting chemokines. Here the authors show that despite the abundance of their ligands, CCR2 and CCR5 do not mediate trafficking of effector CD8 T cells into the tumour, whereas CXCR3 is essential for this process and for T-cell-based elimination of melanoma in mice.
52
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi, Steven O’Day, David F. McDermott et al. · New England Journal of Medicine · 2010 · 15.2K citations · Full text
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer et al. · New England Journal of Medicine · 2012 · 12.7K citations · Full text
Life Sciences, Immunology, Oncology +17
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Jérôme Galon, Anne Costes, Fátima Sánchez‐Cabo et al. · Science · 2006 · 6.5K citations
Medicine, Immunology, Oncology +17
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst, Jean‐Charles Soria, Marcin Kowanetz et al. · Nature · 2014 · 5.3K citations
Medicine, Immunology, Oncology +16
CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis
Bin‐Zhi Qian, Jiufeng Li, Hui Zhang et al. · Nature · 2011 · 2.9K citations · Full text
Medicine, Cancer Biology, Oncology +14